Literature DB >> 33391010

Novel Strategies for Endothelial Preservation in Lung Transplant Ischemia-Reperfusion Injury.

Wolfgang Jungraithmayr1,2,3.   

Abstract

Lung ischemia reperfusion (IR) injury inevitably occurs during lung transplantation. The pulmonary endothelium is the primary target of IR injury that potentially results in severe pulmonary dysfunction. Over the last decades, various molecules, receptors, and signaling pathways were identified in order to develop treatment strategies for the preservation of the pulmonary endothelium against IR injury. We here review the latest and most promising therapeutic strategies for the protection of the endothelium against IR injury. These include the stabilization of the endothelial glycocalyx, inhibition of endothelial autophagy, inhibition of adhesion molecules, targeting of angiotensin-converting enzyme, and traditional viral and novel non-viral gene transfer approaches. Though some of these strategies proved to be promising in experimental studies, very few of these treatment concepts made the transfer into clinical application. This dilemma underscores the need for more experimental evidence for the translation into clinical studies to invent therapeutic concepts against IR injury-mediated endothelial damage.
Copyright © 2020 Jungraithmayr.

Entities:  

Keywords:  endothelium; ischemia-reperfusion injury; lung; strategies; transplantation

Year:  2020        PMID: 33391010      PMCID: PMC7775419          DOI: 10.3389/fphys.2020.581420

Source DB:  PubMed          Journal:  Front Physiol        ISSN: 1664-042X            Impact factor:   4.566


  8 in total

Review 1.  Primary Graft Dysfunction: The Role of Aging in Lung Ischemia-Reperfusion Injury.

Authors:  Maximilian J Roesel; Nirmal S Sharma; Andreas Schroeter; Tomohisa Matsunaga; Yao Xiao; Hao Zhou; Stefan G Tullius
Journal:  Front Immunol       Date:  2022-05-24       Impact factor: 8.786

2.  CYP2J2 and EETs protect against pulmonary arterial hypertension with lung ischemia-reperfusion injury in vivo and in vitro.

Authors:  Yun Ding; Pengjie Tu; Yiyong Chen; Yangyun Huang; Xiaojie Pan; Wenshu Chen
Journal:  Respir Res       Date:  2021-11-13

Review 3.  A Focused Review on Primary Graft Dysfunction after Clinical Lung Transplantation: A Multilevel Syndrome.

Authors:  Jan Van Slambrouck; Dirk Van Raemdonck; Robin Vos; Cedric Vanluyten; Arno Vanstapel; Elena Prisciandaro; Lynn Willems; Michaela Orlitová; Janne Kaes; Xin Jin; Yanina Jansen; Geert M Verleden; Arne P Neyrinck; Bart M Vanaudenaerde; Laurens J Ceulemans
Journal:  Cells       Date:  2022-02-21       Impact factor: 6.600

4.  Postconditioning with Irisin Attenuates Lung Ischemia/Reperfusion Injury by Suppressing Ferroptosis via Induction of the Nrf2/HO-1 Signal Axis.

Authors:  Yun Wang; Zhe Dong; Zongze Zhang; Yanlin Wang; Kun Yang; Xinyi Li
Journal:  Oxid Med Cell Longev       Date:  2022-03-02       Impact factor: 6.543

Review 5.  Novel approaches for long-term lung transplant survival.

Authors:  Cynthia L Miller; Jane M O; James S Allan; Joren C Madsen
Journal:  Front Immunol       Date:  2022-07-27       Impact factor: 8.786

6.  Inhibition of the cGAS-STING Pathway Attenuates Lung Ischemia/Reperfusion Injury via Regulating Endoplasmic Reticulum Stress in Alveolar Epithelial Type II Cells of Rats.

Authors:  Renhui Huang; Qi Shi; Shutian Zhang; Hong Lin; Chengzhi Han; Xinyi Qian; Yijun Huang; Xiaorong Ren; Jiayuan Sun; Nana Feng; Chunmei Xia; Meng Shi
Journal:  J Inflamm Res       Date:  2022-09-05

Review 7.  Ischemia-Reperfusion Injury in Lung Transplantation.

Authors:  Toyofumi Fengshi Chen-Yoshikawa
Journal:  Cells       Date:  2021-05-28       Impact factor: 6.600

8.  Heparanase inhibition preserves the endothelial glycocalyx in lung grafts and improves lung preservation and transplant outcomes.

Authors:  Kentaro Noda; Brian J Philips; Mark E Snyder; Julie A Phillippi; Mara Sullivan; Donna B Stolz; Xi Ren; James D Luketich; Pablo G Sanchez
Journal:  Sci Rep       Date:  2021-06-10       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.